Affordable Access

deepdyve-link
Publisher Website

Feasibility Technique of Low-passage In Vitro Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome.

Authors
  • Vinayanuwattikun, Chanida1
  • Prakhongcheep, Ornjira2, 3
  • Tungsukruthai, Sucharat2, 3
  • Petsri, Korrakod2, 3
  • Thirasastr, Prapassorn1
  • Leelayuwatanakul, Nophol4
  • Chanvorachote, Pithi5, 3
  • 1 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. , (Thailand)
  • 2 Cell-Based Drug and Health Product Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. , (Thailand)
  • 3 Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. , (Thailand)
  • 4 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. , (Thailand)
  • 5 Cell-Based Drug and Health Product Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand [email protected] , (Thailand)
Type
Published Article
Journal
Anticancer Research
Publisher
International Institute of Anticancer Research
Publication Date
Dec 01, 2019
Volume
39
Issue
12
Pages
6981–6988
Identifiers
DOI: 10.21873/anticanres.13920
PMID: 31810970
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Individualized proper chemotherapy using in vitro drug sensitivity testing has been proposed as a novel therapeutic modality and shown to have better efficacy than empiric chemotherapy. However, issues around establishing a patient-derived cell culture or xenograft, the timing of the testing obtained, and the validity of testing represent major limitations to translating the use of such a technique to clinical practice. In this study, we assessed the feasibility of an in vitro drug sensitivity technique for testing malignant pleural effusion from advanced-stage non-small cell lung cancer. Our technique was able to produce a turnaround time for in vitro drug sensitivity testing of less than 1 week, with a success rate of more than 90% of cases. Correlated with the individual clinical outcome, using the area under the dose response curve (AUC) could define the level of in vitro drug sensitivity as: responsive (AUC>0.25), intermediate response (0.1≤AUC≤0.25), or resistance (AUC<0.1). Data obtained from this method of drug testing were correlated with the clinical outcome. The present drug sensitivity evaluation may benefit the development of individual precision chemotherapy. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Report this publication

Statistics

Seen <100 times